Bial R&d Investments, S.a.
Clinical trials sponsored by Bial R&d Investments, S.a., explained in plain language.
-
Free drug access for Parkinson's patients with specific gene mutation
Disease control NO_LONGER_AVAILABLEThis program offers continued free access to the experimental drug BIA 28-6156 for people with Parkinson's disease who have a specific change in the GBA1 gene and have already completed the ACTIVATE study. Participants take one 60mg pill daily. The goal is to provide ongoing trea…
Sponsor: Bial R&D Investments, S.A. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill aims to slow Parkinson's in patients with genetic mutation
Disease control OngoingThis study tests an experimental drug called BIA 28-6156 in people with Parkinson's disease who have a specific change in the GBA1 gene. The goal is to see if the drug can delay the worsening of movement-related daily living skills over 78 weeks. About 237 participants will recei…
Phase: PHASE2 • Sponsor: Bial R&D Investments, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC